Trials / Completed
CompletedNCT04505839
First-In-Human Dose-Escalation Study of STP1002 in Patients With Advanced-Stage Solid Tumors
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 32 (actual)
- Sponsor
- ST Pharm Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is an open-label, multicenter, dose-escalation study to evaluate the safety, tolerability, and pharmacokinetics (PK) and to determine the maximum tolerated dose (MTD) of STP1002 in patients with advanced-stage solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | STP1002 | Oral capsule, QD |
Timeline
- Start date
- 2020-07-30
- Primary completion
- 2023-03-07
- Completion
- 2023-03-07
- First posted
- 2020-08-10
- Last updated
- 2024-07-03
Locations
3 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04505839. Inclusion in this directory is not an endorsement.